Platinum-based antitumor drugs have been used in many types of tumors due to its broad
antitumor spectrum in clinic. Encouraged by the cisplatin's (CDDP) worldwide success in …

Platinum (II)-based drugs are widely used for the treatment of solid tumors, especially in
combination protocols. Severe side effects and occurrence of resistance are the major …

Ferroptosis therapy, which applies ferroptotic inducers to produce lethal lipid peroxidation
and induce the death of tumor cells, is regarded as a promising therapeutic strategy for …

With the highest incidence, breast cancer is the leading cause of cancer deaths among
women in the world. Tumor metastasis is the major contributor of high mortality in breast …

Acquired resistance remains a major barrier for the treatment of non-small cell lung cancer,
while cancer stem cells (CSCs) usually lead to the occurrence of drug resistance. We herein …

This review highlights the progress in the development of ruthenium (II)/(III) complexes with
flavone derivatives as potential therapeutic agents. We focused on natural hydroxyflavone …

“Multi-action” Pt (IV) derivatives of cisplatin with combretastatin A4 (CA4) bioactive ligands
that are conjugated to Pt (IV) by carbonate are unique because the ligand (IC50< 10 nM) is …

The concept of multi-action octahedral platinum (IV) complexes is based on the rational
derivatization of anticancer square-planar platinum (II) compounds (eg, cisplatin or …

Cancer stem cells (CSC) are a sub-population of tumours linked to metastasis and relapse.
Current chemotherapeutic drug options are ineffective against CSCs at their administered …

The application of G‐quadruplex stabilizers presents a promising anticancer strategy.
However, the molecular crowding conditions within cells diminish the potency of current G …